Neuroinflammation Imaging in AD

Evaluation of in Vivo Neuroinflammation in Alzheimer's Disease Using Novel Positron Emission Tomography (PET/CT) Imaging

This study is trying to see if imaging techniques can help us understand inflammation in the brains of people with Alzheimer's disease.

Quick facts

• Phase: EARLY_PHASE1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 55 Years and up
• Sex: All
• Sponsor: University of Pennsylvania (other)
• Locations: 1 site (Philadelphia, Pennsylvania)
• Trial ID: NCT04274998 on ClinicalTrials.gov

What this trial studies

Processing failed - manual review needed

Who should consider this trial

Good fit: Unknown

Not a fit: Unknown

Why it matters

Potential benefit: Unknown

How similar studies have performed: Unknown

Eligibility criteria

Inclusion Criteria (HC cohort only):

1. - Males and females ≥ 55 years of age
2. Part of the UPenn ADC research cohort with designation of cognitively normal per ADC database.
3. A brain amyloid PET scan ≤ 1 year prior to enrollment in this study that is determined to be negative by the study PI.
4. Mini-mental status exam (MMSE) score of 28 or higher per ADC database.
5. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Inclusion Criteria (AD/MCI cohort only)

1. Males and females ≥ 55 years of age
2. Part of the Upenn ADC research cohort with designation that the presence of Alzheimer's pathology is likely per ADC database.
3. A brain amyloid PET scan ≤ 1 year prior to enrollment in this study that is determined to be positive by the study PI.
4. Mini-mental status exam (MMSE) score of 14-27 per ADC database.
5. Subjects must have a designated study partner to accompany them to study visits

Inclusion Criteria 11C-PBR28 sub-study (both HC and AD/MCI cohorts)

1. High affinity carrier of the rs6971 TSPO polymorphism (whole genome sequencing is available from the UPenn ADC research cohort and will be interrogated for this polymorphism)

Exclusion Criteria (HC and PD cohorts):

1. Females of child-bearing potential will not be included, female subjects must be post-menopausal or surgically sterile
2. History of epilepsy or seizure disorder as assessed by medical record review and/or self-report
3. History of head trauma or evidence of structural abnormalities such as a major stroke or mass on MRI that in the opinion of an investigator may interfere with the uptake of applicable radiotracer as assessed by medical record review and/or self-report
4. Current tobacco or nicotine dependence. History of greater than 5 pack years of smoking and less than 2 years since smoking cessation.
5. Have a history of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported
6. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
7. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study

Where this trial is running

Philadelphia, Pennsylvania

• University of Pennsylvania — Philadelphia, Pennsylvania, United States (RECRUITING)

Study contacts

• Study coordinator: Erin Schubert

Conditions: Alzheimer Disease, Healthy Volunteer